The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
Open accessAbstract
The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome, but 5–10% of cases will develop metastatic disease. Around 60–70% of this subset, hence less than 5% of all patients with TC, will become radioiodine refractory (RAI-R), with a significant negative impact on prognosis and a mean life expectancy of 3–5 years. Since no European expert consensus or guidance for this challenging condition is currently available, a task force of TC experts was nominated by the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. The task force started to work in September 2018 and after several revision rounds, prepared a list of recommendations to support the treatment and follow-up of patients with advanced TC. Criteria for advanced RAI-R TC were proposed, and the most appropriate diagnostic tools and the local, systemic and palliative treatments are described. Systemic therapy with multikinase inhibitors is fully discussed, including recommendations on how to start it and at which dosage, on the duration of treatment, and on the management of side effects. The appropriate relationship between the specialist and the patient/family as well as ethical issues are covered. Based on the available studies and on personal experience, the experts provided 39 recommendations aimed to improve the management of advanced RAI-R TCs. Above all of them is the indication to treat and follow these patients in a specialized setting which allows the interaction between several specialists in a multidisciplinary team.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Self-citationDurante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Self-citationBrose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Self-citationStopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Self-citationGenomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 727
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Volante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180309e6a · Cited by 619
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 587
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Orloff, L. A., Wiseman, S. M., Bernet, V. J., Fahey, T. J., Shaha, A. R., Shindo, M. L., Snyder, S. K., Stack, B. C., Sunwoo, J. B., Wang, M. B., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0309 · Cited by 516
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Tuttle, R. M., Ahuja, S., Avram, A. M., Bernet, V. J., Bourguet, P., Daniels, G. H., Dillehay, G., Draganescu, C., Flux, G., Führer, D., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0597 · Cited by 413
Self-citationSchwartz, L. H., Seymour, L., Litière, S., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.082 · Cited by 380
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F., & Pacini, F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70215-8 · Cited by 377
Self-citationUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Liu, R., Bishop, J., Zhu, G., Zhang, T., Ladenson, P. W., & Xing, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3288 · Cited by 296
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
Silberstein, E. B., Alavi, A., Balon, H. R., Clarke, S. E. M., Divgi, C., Gelfand, M. J., Goldsmith, S. J., Jadvar, H., Marcus, C. S., Martin, W. H., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.105148 · Cited by 287
Antoun, S., Birdsell, L., Sawyer, M. B., Venner, P., Escudier, B., & Baracos, V. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9730 · Cited by 283
Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., Takamura, Y., Higashiyama, T., Fukushima, M., Kihara, M., Inoue, H., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0355 · Cited by 265
Ras is involved in nerve-activity-dependent regulation of muscle genes
Murgia, M., Serrano, A. L., Calabria, E., Pallafacchina, G., Lømo, T., & Schiaffino, S. (2000) · Nature Cell Biology · doi:10.1038/35004013 · Cited by 218
Rivera, M., Ghossein, R. A., Schoder, H., Gomez, D., Larson, S. M., & Tuttle, R. M. (2008) · Cancer · doi:10.1002/cncr.23515 · Cited by 211
Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M. D., & Hurria, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6472 · Cited by 200
Self-citationCabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., Topliss, D., et al. (2015) · Cancer · doi:10.1002/cncr.29395 · Cited by 186
Self-citationHenry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-013-2022-1 · Cited by 183
Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J. P., Talbot, M., Lumbroso, J., Baudin, E., Caillou, B., Bidart, J. M., et al. (2011) · Endocrine Related Cancer · doi:10.1677/erc-10-0233 · Cited by 177
Self-citationManagement of Sorafenib-Related Adverse Events: A Clinician’s Perspective
Brose, M. S., Frenette, C. T., O’Keefe, S. J., & Stein, S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.01.001 · Cited by 141
HAY, I. D., Lee, R. A., Davidge-Pitts, C. J., Reading, C. C., & Charboneau, J. W. (2013) · Surgery · doi:10.1016/j.surg.2013.07.007 · Cited by 130
Schneider, T., Abdulrahman, R. M., Corssmit, E. P. M., Morreau, H. M., Smit, J. W. A., & Kapiteijn, E. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0405 · Cited by 130
Self-citationLenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice
Berdelou, A., Borget, I., Godbert, Y., Nguyen, T., Garcia, M.-E., Chougnet, C., Ferru, A., Buffet, C., Chabre, O., Huillard, O., et al. (2017) · Thyroid · doi:10.1089/thy.2017.0205 · Cited by 129
Self-citationSpecial types of thyroid carcinoma
Baloch, Z. W., & LiVolsi, V. A. (2017) · Histopathology · doi:10.1111/his.13348 · Cited by 123
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Abdulrahman, R. M., Verloop, H., Hoftijzer, H., Verburg, E., Hovens, G. C., Corssmit, E. P., Reiners, C., Gelderblom, H., Pereira, A. M., Kapiteijn, E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2507 · Cited by 112
Self-citationHaddad, R. I., Schlumberger, M. J., Wirth, L. J., Sherman, E. J., Shah, M. H., Robinson, B. G., Dutcus, C. E., Teng, A., Gianoukakis, A. G., & Sherman, S. I. (2017) · Endocrine · doi:10.1007/s12020-017-1233-5 · Cited by 111
Wirth, L. J., Tahara, M., Robinson, B. G., Francis, S. A., Brose, M. S., Habra, M. A., Newbold, K. L., Kiyota, N., Dutcus, C. E., Mathias, E. G., et al. (2018) · Cancer · doi:10.1002/cncr.31344 · Cited by 108
Self-citationMassicotte, M.-H., Borget, I., Broutin, S., Baracos, V. E., Leboulleux, S., Baudin, É., Paci, A., Deroussent, A., Schlumberger, M. J., & Antoun, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1115 · Cited by 102
Self-citationSabra, M. M., Sherman, E. J., & Tuttle, R. M. (2017) · Cancer · doi:10.1002/cncr.30690 · Cited by 96
Prolonged duration of response in lenvatinib responders with thyroid cancer
Gianoukakis, A. G., Dutcus, C. E., Batty, N., Guo, M. D., & Baig, M. A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0049 · Cited by 96
Robinson, B. G., Schlumberger, M. J., Wirth, L. J., Dutcus, C. E., Song, J., Taylor, M. H., Kim, S., Krzyzanowska, M. K., Capdevila, J., Sherman, S. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3989 · Cited by 95
Qi, W., Shen, Z., Tang, L., & Yao, Y. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12387 · Cited by 92
Leboulleux, S., Bez, I. E., Borget, I., Elleuch, M., Deandreis, D., Ghuzlan, A. A., Chougnet, C., Bidault, F., Mirghani, H., Lumbroso, J., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0081 · Cited by 90
Self-citationZoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma
Orita, Y., Sugitani, I., Toda, K., Manabe, J., & Fujimoto, Y. (2010) · Thyroid · doi:10.1089/thy.2010.0169 · Cited by 89
Incidental Thyroid Nodules and Thyroid Cancer: Considerations Before Determining Management
Tufano, R. P., Noureldine, S. I., & Angelos, P. (2015) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2015.0647 · Cited by 82
Zhang, Z., Wang, T., Liu, L., & Guo, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090135 · Cited by 82
Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications
Nostrand, D. V. (2018) · Thyroid · doi:10.1089/thy.2018.0048 · Cited by 74
Sabra, M. M., Grewal, R. K., Tala, H., Larson, S. M., & Tuttle, R. M. (2012) · Thyroid · doi:10.1089/thy.2011.0429 · Cited by 63
Poorly differentiated oncocytic thyroid carcinoma – diagnostic implications and outcome
Dettmer, M. S., Schmitt, A. M., Steinert, H. C., Moch, H., Komminoth, P., & Perren, A. A. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04188.x · Cited by 61
Cementoplasty of bone metastases
Deschamps, F., & de Baère, T. (2012) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2012.06.009 · Cited by 49
Kist, J. W., de Keizer, B., van der Vlies, M., Brouwers, A. H., Huysmans, D. A., van der Zant, F. M., Hermsen, R., Stokkel, M. P. M., Hoekstra, O. S., & Vogel, W. V. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168138 · Cited by 47
Colombo, C., De Leo, S., Di Stefano, M., Vannucchi, G., Persani, L., & Fugazzola, L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01836 · Cited by 44
Self-citationLenvatinib-induced renal failure: two first-time case reports and review of literature
Cavalieri, S., Cosmai, L., Genderini, A., Nebuloni, M., Tosoni, A., Favales, F., Pistillo, P., Bergamini, C., Bossi, P., Licitra, L. F., et al. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461839 · Cited by 38
Hortobágyi, G. N., Lipton, A., Chew, H. K., Gradishar, W. J., Sauter, N. P., Mohanlal, R. W., Zheng, M., McGrain, B., & Poznak, C. H. V. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba9500 · Cited by 36
Dunne, E. M., Fraser, I., & Liu, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.40 · Cited by 34
Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma
Sherman, S. I. (1999) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199901/02)16:1<34::aid-ssu7>3.0.co;2-2 · Cited by 30
Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
Weitzman, S. P., & Sherman, S. I. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.10.009 · Cited by 27
Clinical and Professional Ethics Guidelines for the Practice of Thyroidology
Rosenthal, M. S., Angelos, P., Cooper, D. S., Fassler, C., Finder, S. G., Hays, M. T., Tendler, B. E., & Braunstein, G. D. (2013) · Thyroid · doi:10.1089/thy.2013.0124 · Cited by 26
Molina‐Vega, M., Garcı́a-Alemán, J., Sebastián-Ochoa, A., Mancha-Doblas, I., Trigo, J. M., & Tinahones, F. J. (2017) · Endocrine · doi:10.1007/s12020-017-1499-7 · Cited by 25
Choy, P. Y. G., Koea, J., McCall, J. L., Holden, A. H., & Osbourne, M. (2002) · PubMed · Cited by 22
Sorafenib therapy decreases the clearance of thyrotropin
Verloop, H., Smit, J. W. A., & Dekkers, O. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0828 · Cited by 21
Self-citationThe role of external beam radiation therapy in well-differentiated thyroid cancer
Hamilton, S. N., Tran, E., Berthelet, E., & Wu, J. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1361324 · Cited by 19
Cited by
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Boucai, L., Zafereo, M., & Cabanillas, M. E. (2024) · JAMA · doi:10.1001/jama.2023.26348 · Cited by 701
Brose, M. S., Robinson, B., Sherman, S. I., Krajewska, J., Lin, C.-C., Vaisman, F., Hoff, A. O., Hitre, E., Bowles, D. W., Hernando, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00332-6 · Cited by 256
Metadata
- Authors
- Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., & Smit, J.
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2019
- Volume
- 8
- Issue
- 5
- Pages
- 227-245
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- OpenAlex
- W2976988657
- Cited by
- 285
- References
- 65
- FWCI
- 23.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.